- About us
- Clinical trials
- News & Publications
SOTIO Bolsters Leadership Team with Appointment of Martin Steegmaier as Chief Scientific Officer
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced the appointment of Martin Steegmaier, Ph.D., MBA, as chief scientific officer. Martin Steegmaier brings over 20 years of experience in oncology drug discovery, drug development and business development. His extensive knowledge of the biotech industry and clinical immuno-oncology will be crucial as SOTIO continues to advance multiple assets through the clinic. He will be responsible for preclinical and translational research globally.
SOTIO Strengthens Management Team with Appointment of Robyn Hunter as Chief Financial Officer
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announces the appointment of Robyn Hunter as chief financial officer. Ms. Hunter is an accomplished CFO who brings an extensive array of financial experience to SOTIO, including her extensive knowledge of biotech and capital markets. She joins SOTIO to oversee the long-term financing strategy.
SOTIO Announces Clinical Collaboration with MSD to evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., through its subsidiaries, to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® (pembrolizumab) in patients with selected advanced/refractory solid tumors in the phase 2 AURELIO-04 study.